

The genetic architecture of left ventricular non-compaction reveals both substantial overlap with other cardiomyopathies and a distinct aetiology in a subset of cases

Supplemental Methods

LVNC cohorts included in this study

Two of the six cohorts analysed were unpublished:

- 32 unrelated cases with a diagnosis of LVNC were sequenced by the cardiac genetics service at Careggi University Hospital in Florence, Italy. All patients underwent genetic testing from 2013 onwards, with those tested until mid-2017 (N=27) sequenced on a panel comprising 111 genes implicated in cardiomyopathies, and those tested later (N=5) sequenced on the 174-genes Illumina TruSight Cardio panel (Table S1).
- 233 unrelated cases with a definitive diagnosis of LVNC were sequenced by the Laboratory of Molecular Medicine, Partner's Healthcare, Boston, USA. Patients with indications that suggest a syndromic form of LVNC (i.e. including non-cardiac symptoms) or only with suspected LVNC were excluded from the analysis. As the gene panels used evolved over time, the number of cases sequenced ranged from 36 to 231 depending on gene (Table S1).

The other four cohorts analysed were previously published:

- van Waning *et al.* described a cohort of up to 327 LVNC probands from four cardiogenetic centres in the Netherlands¹, sequenced on panels of cardiomyopathy genes. LVNC diagnosis was based on evaluation of echocardiography and magnetic resonance imaging using the Jenni and Peterson criteria.
- Richard *et al.* described a cohort of 95 adult LVNC probands enrolled between 2012 and 2013 in 13 French centres for inherited cardiac diseases², sequenced on a 107 gene cardiomyopathy and arrhythmia panel. All patients had a recent diagnosis of isolated LVNC (within 6 months of inclusion in the study) with echocardiography reviewed by a core lab to confirm diagnosis.
- Misalski-Jamka *et al.* described a cohort of 174 probands³ – 90 were diagnosed with LVNC (a two-layered trabeculated and compacted LV myocardium with maximum NC/C ratio >2.3:1) with 84 cases described as having left ventricular hypertrabeculation (LVHT), i.e. cases that failed to meet the criteria for LVNC diagnosis but were suspected of having LVNC. Only the 90 definitive LVNC cases in this cohort were used for this meta-analysis.
- Sixty-three LVNC cases were assessed by Klaassen *et al.*⁴ (sequencing of 6 sarcomeric genes) and Probst *et al.*⁵ (2 sarcomeric genes). These cases were diagnosed with established criteria, a NC/C ratio >2 with prominent trabeculations and deep intertrabecular recesses, in the absence of congenital heart anomalies. An expanded version of this cohort, comprising 75 LVNC cases, were sequenced for *PRDM16* by Arndt *et al.*⁶. As these cases were defined as lacking mutations in sarcomeric genes, the denominator used for *PRDM16* in this cohort was 93 cases (to include the 18 genotype positive cases from the sarcomeric gene studies from this cohort and avoid inflating the frequency of *PRDM16* variants).

Defining rare variants

Rare variants were defined as having a filtering allele frequency (FAF) in gnomAD exomes (v 2.1) less than 0.0001. FAFs are defined as the highest disease-specific maximum credible population allele frequency for which the observed allele count is not compatible with pathogenicity. The threshold of 0.0001 was applied in our previous study on rare variant association analysis in cardiomyopathies⁷ and has been demonstrated to be an appropriate level based on the specific characteristics (prevalence, genetic heterogeneity and penetrance) in cardiomyopathies⁸. To be defined as rare, variants had to be below this threshold for both the popmax FAF (highest allele frequency of the major sub-populations of gnomAD – African, East Asian, Latino, non-Finnish European and South Asian) and the overall FAF (to filter variants that may be enriched in the gnomAD founder populations – Ashkenazi Jewish and Finnish).

Specific additional analysis for RBM20, HCN4 and RYR2

In addition to assessing overall gene level rare variant frequencies for truncating and non-truncating variants, further analysis of specific variant classes was performed for three genes (*RBM20*, *HCN4* and *RYR2*) based on previously published reports on the pathogenicity of such variants (described in detail in Table 4). For *RBM20*, non-truncating variants in the established pathogenic hotspot between residues 634 and 638 inclusive were assessed^{9,10}. For *HCN4*, non-truncating variants in the transmembrane region of the channel were assessed (amino acid residues 267 to 517 as defined by Uniprot entry Q9Y3Q4).

For *RYR2*, we additionally assessed the frequency of structural variants (SVs) in LVNC cases and controls. As controls, we used the recently added SV dataset in gnomAD, derived from whole genome sequencing of 14,891 individuals¹¹. Of note, the detection of SVs requires particular assays and/or analysis pipelines, and it is uncertain whether all of the constituent studies in this analysis were designed to detect such variants. However, we have decided to use the total number of cases where *RYR2* is sequenced (429) to provide a conservative estimate of the contribution of these variants in LVNC.

Cardiomyopathy cohorts

For comparison to the burden of rare variation in dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM), variants from cardiomyopathy cases from previously published studies or unpublished data from cardiomyopathy cohorts at the Royal Brompton Hospital were used and re-analysed using the same methods as with the LVNC data. Specifically, previously published data from clinical genetics cohorts from the Oxford Molecular Genetics Laboratory (OMGL), UK, and the Laboratory of Molecular Medicine (LMM), USA was used for *ACTC1*, *ACTN2*, *MYBPC3*, *MYH7*, *TNNT2*, *TPM1* and *TTN* (for DCM) and *ACTC1*, *ACTN2*, *MYBPC3*, *MYH7*, *TNNT2* and *TPM1* (for HCM)⁷. For the remaining genes – *HCN4*, *PRDM16* and *RBM20* (for DCM and HCM) and *TTN* (for HCM), previously unpublished data from cardiomyopathy outpatient clinic cohorts from the Royal Brompton Hospital, UK, was used, comprising up to 863 unrelated DCM patients and up to 685 unrelated HCM patients. See Table S3 for details of the number of DCM and HCM cases analysed for each gene.

RNA analysis of MYH7:c.732+1G>A variant

Blood from carriers of the *MYH7*:c.732+1G>A variant in the Italian pedigree was collected in PAXgene Blood RNA Tubes (Preanalytix Cat No.: 762165). RNA was isolated according to the protocol from the kit PAXgene Blood RNA kit (Preanalytix Cat no.: 762174). cDNA was synthesized with the SuperScript™ II Reverse Transcriptase kit (Invitrogen Cat no.: 18064071); whereby the input total RNA was 500ng/sample/reaction. Random hexamers (50pmol/rxn) (Invitrogen Cat no.: N8080127) were used as well as a mix of Random Hexamers (50pmol/rxn) and OligodT-primers (125pmol/rxn) for cDNA synthesis. After synthesis, cDNA was 4x diluted for use in LightCycler480 experiments. Primers used for amplifying *MYH7* transcripts were: *MYH7*_6/7Forw (5'-CTGGATGATCTACACCTACTCG-3') with *MYH7*_int8_9R (5'-CTGGAGAGATGGAAGAGAGTG-3') and *MYH7*_31_32F (5'-GCAGAGGAACTTCGACAAGATC-3') with *MYH7*_34_Rev (5'-CTGCCTTGATCTGGTTGAACTC-3'); 5pmol of each primer was used per primer-pair/reaction, annealing temperature 57.7 degrees Celsius. We were unable to amplify any detectable *MYH7* product in these samples.

Supplemental Tables

Supplemental Table 1: List of genes and Ensembl transcripts analysed in this study (i.e. those analysed in $\geq 50\%$ of the constituent cohorts). The number of LVNC probands sequenced for each gene in each cohort is shown, along with the total number of cases analysed for each gene in this meta-analysis.

Supplemental Table 2: List of all rare, protein-altering variants detected in the LVNC cases analysed in this meta-analysis for the genes in Table S1. Rarity is defined as a gnomAD exomes (v2.1) filtering allele frequency (overall and popmax) < 0.0001 . The variant classes included are frameshift, nonsense and essential splice site (truncating), missense and inframe insertions/deletions (non-truncating) and exon deletions (structural variants). The number of cases in which the variant is detected (per cohort) is also shown.

Supplemental Table 3: For the genes/variant classes enriched in LVNC, we compared rare variant frequencies and enrichment over gnomAD population controls in dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM) cohorts described here. OMGL/LMM indicates data from clinical genetics cohorts from the Oxford Molecular Genetics Laboratory (UK) and the Laboratory of Molecular Medicine (Boston, USA), previously published by Walsh et al (Genet. Med. 2017). Royal Brompton indicates prospective cohorts from outpatient clinics at the Royal Brompton Hospital (London, UK), with up to 863 DCM probands and up to 685 HCM probands sequenced on the TruSight Cardio panel.

Supplemental Table 4: Results for rare variant burden testing in LVNC cases versus gnomAD exomes (v2.1) population controls. Data for truncating and non-truncating variants in 70 genes are shown, as well non-truncating variants within and without the *HCN4* transmembrane region and the *RBM20* pathogenic hotspot and structural variants (exon deletions) in *RYR2* (compared to the gnomAD structural variants dataset). Variant counts and rare variant frequencies for LVNC and gnomAD are displayed, as well as the excess of rare variants in LVNC and the p value for the Fisher's exact test.

Supplemental Table 5: Frequencies of rare variants in each of the constituent LVNC cohorts for the variants classes significantly enriched in LVNC compared to gnomAD exomes population controls.

Supplemental Table 6: Frequency details for the common *MYH7* splice region variant, c.732C>T, in the newly described LVNC cohorts of this study and the appropriate gnomAD sub-populations. P values are from a two tailed Fisher's exact test. Ethnicities for the LMM cases are self-declared.

Supplemental Table 7: Details of the LVNC cases with rare variants in the genes/variant classes that are enriched in LVNC but not enriched in DCM or HCM – *ACTN2* truncating variants, *HCN4* missense variants in the transmembrane region, *PRDM16* truncating variants and *RYR2* exon deletions. See table 3 in the manuscript for details LVNC cases with *MYH7* truncating variants.

Supplemental References

1. van Waning JI, Caliskan K, Hoedemaekers YM, van Spaendonck-Zwarts KY, Baas AF, Boekholdt SM, van Melle JP, Teske AJ, Asselbergs FW, Backx APCM, du Marchie Sarvaas GJ, Dalinghaus M, Breur JMPJ, Linschoten MPM, Verlooi LA, Kardys I, Dooijes D, Lekanne Deprez RH, Ijpma AS, van den Berg MP, Hofstra RMW, van Slegtenhorst MA, Jongbloed JDH, Majoor-Krakauer D. Genetics, Clinical Features, and Long-Term Outcome of Noncompaction Cardiomyopathy. *J Am Coll Cardiol*. 2018;71:711–722.
2. Richard P, Ader F, Roux M, Donal E, Eicher J-C, Aoutil N, Huttin O, Selton-Suty C, Coisne D, Jondeau G, Damy T, Mansencal N, Casalta A-C, Michel N, Haentjens J, Faivre L, Lavoute C, Nguyen K, Tregouët D-A, Habib G, Charron P. Targeted panel sequencing in adult patients with left ventricular non-compaction reveals a large genetic heterogeneity. *Clin Genet*. 2019;95:356–367.
3. Misalski-Jamka K, Jefferies JL, Mazur W, Głowacki J, Hu J, Lazar M, Gibbs RA, Liczko J, Kłyś J, Venner E, Muzny DM, Rycaj J, Białkowski J, Kluczevska E, Kalarus Z, Jhangiani S, Al-Khalidi H, Kukulski T, Lupski JR, Craigen WJ, Bainbridge MN. Novel Genetic Triggers and Genotype-Phenotype Correlations in Patients With Left Ventricular Noncompaction. *Circ Cardiovasc Genet*. 2017;10.
4. Klaassen S, Probst S, Oechslin E, Gerull B, Krings G, Schuler P, Greutmann M, Hürlimann D, Yegitbasi M, Pons L, Gramlich M, Drenckhahn J-D, Heuser A, Berger F, Jenni R, Thierfelder L. Mutations in sarcomere protein genes in left ventricular noncompaction. *Circulation*. 2008;117:2893–901.
5. Probst S, Oechslin E, Schuler P, Greutmann M, Boyé P, Knirsch W, Berger F, Thierfelder L, Jenni R, Klaassen S. Sarcomere gene mutations in isolated left ventricular noncompaction cardiomyopathy do not predict clinical phenotype. *Circ Cardiovasc Genet*. 2011;4:367–74.
6. Arndt A-K, Schafer S, Drenckhahn J-D, Sabeh MK, Plovie ER, Caliebe A, Klopocki E, Musso G, Werdich AA, Kalwa H, Heinig M, Padera RF, Wassilew K, Bluhm J, Harnack C, Martitz J, Barton PJ, Greutmann M, Berger F, Hubner N, Siebert R, Kramer H-H, Cook SA, MacRae CA, Klaassen S. Fine mapping of the 1p36 deletion syndrome identifies mutation of PRDM16 as a cause of cardiomyopathy. *Am J Hum Genet*. 2013;93:67–77.
7. Walsh R, Thomson KL, Ware JS, Funke BH, Woodley J, McGuire KJ, Mazzarotto F, Blair E, Seller A, Taylor JC, Minikel E V, Exome Aggregation Consortium, MacArthur DG, Farrall M, Cook SA, Watkins H. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. *Genet Med*. 2017;19:192–203.
8. Whiffin N, Minikel E, Walsh R, O'Donnell-Luria AH, Karczewski K, Ing AY, Barton PJR, Funke B, Cook SA, MacArthur D, Ware JS. Using high-resolution variant frequencies to empower clinical genome interpretation. *Genet Med*. 2017;19:1151–1158.
9. Brauch KM, Karst ML, Herron KJ, de Andrade M, Pellikka PA, Rodeheffer RJ, Michels V V, Olson TM. Mutations in ribonucleic acid binding protein gene cause familial dilated cardiomyopathy. *J Am Coll Cardiol*. 2009;54:930–41.
10. Li D, Morales A, Gonzalez-Quintana J, Norton N, Siegfried JD, Hofmeyer M, Hershberger RE. Identification of novel mutations in RBM20 in patients with dilated cardiomyopathy. *Clin Transl Sci*. 2010;3:90–7.
11. Collins RL, Brand H, Karczewski K et al. An open resource of structural variation for medical and population genetics. *bioRxiv*. 2019;doi.org/10.1101/578674.